Lakefront Biotherapeutics NV
LKFT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001421876
No open-market purchases or sales by Lakefront Biotherapeutics NV insiders were filed in the last 90 days; 78 institutions reported holding it in 13F filings for Q2 2026, worth $960.3M in total; Greenlight Capital is the only superinvestor holding it.
Other share classesGLPGF
Key figures
- Market capADS ratio not in SEC data
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −11 vs. previous quarter
- 78
- 13F valueReported value at the end of Q2 2026
- $960.3M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in EUR.
- Revenue, FY2025
- EUR 1.11B
- +303.5% year over year
- Net income, FY2025
- EUR 320.9M
- +333.1% year over year
- Free cash flow, FY2025
- EUR -271.2M
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 1.30M
- Shares sold short
- Change
- −116.8K
- −8.3% vs. previous
- Days to cover
- 5.96
- At average daily volume
Superinvestors holding LKFT, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Lakefront Biotherapeutics NV on Form 13F. Percentages are the stock's share of each portfolio.
Greenlight Capital
David Einhorn
0.4%
Lakefront Biotherapeutics NV's share of the portfolio
- Shares
- 482,746
- Value
- $14.5M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Lakefront Biotherapeutics NV insiders from Form 4, newest first.
No open-market purchases or sales by Lakefront Biotherapeutics NV insiders are on file.
Top 10 13F holders, Q2 2026
See all 78 holdersThe largest institutional positions in Lakefront Biotherapeutics NV at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 16,707,477 | $500.2M | 30.34% | 00.0% | Unchanged |
| Tang Capital Management LLC | 3,785,991 | $113.5M | 5.16% | 00.0% | Unchanged |
| Madison Avenue Partners, LP | 3,447,807 | $103.4M | 4.45% | +982,628+39.9% | Added |
| Prosight Management, LP | 2,043,344 | $61.3M | 10.56% | +493,344+31.8% | Added |
| EcoR1 Capital, LLC | 1,667,119 | $50.0M | 2.48% | 00.0% | Unchanged |
| Ameriprise Financial Inc | 1,272,249 | $38.1M | 0.01% | −152,425−10.7% | Reduced |
| DME Capital Management, LPSuperinvestorGreenlight Capital | 482,746 | $14.5M | 0.37% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 407,800 | $12.2M | 0.02% | +92,400+29.3% | Added |
| BlackRock, Inc. | 338,152 | $10.1M | 0.00% | +26,046+8.3% | Added |
| Point72 Asset Management, L.P. | 269,814 | $8.09M | 0.01% | −62,311−18.8% | Reduced |
Holders of 5% or more of LKFT
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Lakefront Biotherapeutics NV.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 13D/A | 29.90%21.0M shares | – | May 2, 20242 filings | Jan 10, 2025 | SEC |
| EcoR1 Capital, LLC | 13D/A | 13.22%8.71M shares | +1.38 ppfrom 11.84% | Feb 3, 20228 filings | Jul 28, 2025 | SEC |
| Tang Capital Management LLC | 13G | 8.40%5.56M shares | +0.90 ppfrom 7.50% | Feb 14, 20252 filings | Oct 29, 2025 | SEC |
| Madison Avenue Partners, LP | 13G | 5.50%3.61M shares | New | Jun 23, 20261 filing | Jun 23, 2026 | SEC |